FTSE MIB
33.903,78 -367,34 (-1,07%) Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,54 -0,27 (-0,33%) Bitcoin EUR
59.060,37 -2.874,05 (-4,64%)
Ayala Pharmaceuticals, Inc. (ADXS)
| Chiusura precedente | 0,5400 |
| Aperto | 0,5400 |
| Denaro | 0,0000 x 3000 |
| Lettera | 0,0000 x 1000 |
| Min-Max giorno | 0,5400 - 0,5400 |
| Intervallo di 52 settimane | 0,5000 - 1,9500 |
| Volume | |
| Media Volume | 22.354 |
| Capitalizzazione | 23,001M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,5100 |
| Prossima data utili | 21 mag 2024 - 27 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided
- GlobeNewswire
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society for Molecular Oncology (ESMO) Congress 2023, to be held in Madrid, Spain 20-24 October 2023. Poster Presentation DetailsTitle:Phase 2 Results from the RINGSIDE Phase 2/3 Trial of AL102 for Treatment of Desmoi
- GlobeNewswire
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Israel and MONMOUTH JUNCTION, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, and Biosight Ltd., a privately-held pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders,
